A total of 27,642 shares changed hands on the counter till 11:12AM (IST)

The stock quoted a 52-week high of Rs 1266.95 and a 52-week low of Rs 628.1.

On the technical charts, the RSI of the stock stood at 65.72.

A total of 16,040 shares changed hands on the counter till 11:11AM (IST).

The breakout zone, coinciding with a bullish gap at 19,580-19,500, is viewed as robust support, and prices also defended the 19,700 level during the week, serving as immediate support.

Banks are underperforming despite very good results because they are over-owned and sustained FII selling is weighing on bank stocks, said analysts.

On November 23, Lupin announced receiving the USFDA's tentative approval for its Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets to market a generic equivalent of Invokana Tablets of Janssen Pharmaceuticals, Inc at its Pithampur facility.

This product will be manufactured at Lupin’s Pithampur facility in India

Lets first understand how this conclusion is reached that whether the stock has seen a buildup of fresh short position or not.

India has more than 37 million individuals struggling with COPD

A total of 31,191 shares changed hands on the counter till 12:22PM (IST).

Positive setup was seen in Oberoi Realty, MFSL, Ashok Leyland, SBI Life, Aurobindo Pharma, Astral, HDFC Life, Alkem, Lupin, JSW Steel, Titan, RIL, Exide Industries, etc. among others.

A total of 4,842 shares changed hands on the counter till 10:45AM (IST)

The stock quoted a 52-week high of Rs 1238.15 and a 52-week low of Rs 628.1.

Lupin Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Services, Export Incentives and Other Operating Revenue for the year ending 31-Mar-2023.

Prabhudas Lilladher recommended hold rating on Lupin with a target price of Rs 1200 in its research report dated November 10, 2023.

The product will be manufactured at Lupin’s Nagpur facility in India.

A total of 6,241 shares changed hands on the counter till 10:30AM (IST)

Sharekhan recommended Hold rating on Lupin with a target price of Rs 1274 in its research report dated November 10, 2023.

A total of 5,140 shares changed hands on the counter till time (IST).

A total of 49,417 shares changed hands on the counter till 12:58PM (IST).

Lupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon.

Sharekhan is bullish on Trent has recommended buy rating on the stock with a target price of Rs 2750 in its research report dated November 06, 2023.

A total of 73,327 shares changed hands on the counter till 02:04PM (IST)

Ranibizumab is used in the treatment of various age related eye conditions.

Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 53688.88 Crore) operating in Pharmaceuticals sector.

“In pharma, it is better to buy a basket now than individually because select stocks have been outperformers and you want to participate in the whole basket. As a disclosure, Lupin and Aurobindo are two which we have accumulated. We still think that there is upside in both those stocks.”

A total of 67,682 shares changed hands on the counter till 10:15AM (IST)

The strong performance in the US market, aided by the launch of blockbuster respiratory drug Spiriva was the major growth driver for Lupin in Q2

There is a list of upcoming films and series that will be available to the audience in 2024 like The Wages of Fear, GTMax, Nice Girls, and Fiasco.

A total of 33,161 shares changed hands on the counter till 11:41AM (IST)

The company has received tentative approval from the USFDA for its abbreviated new drug application (ANDA) for Canagliflozin and Metformin Hydrochloride Extended-Release Tablets.

According to its latest letter to shareholders, it added 8.8 million new subscribers in the third quarter of 2023, on top of the 5.9 million it gained in the three months before that. The total number of subscribers worldwide is now 247.2 million.

This approval allows Lupin to market a generic version of Uptravi for Injection, 1800 mcg/vial, which is originally produced by Actelion Pharmaceuticals US, Inc

The stock quoted a 52-week high of Rs 1215.2 and a 52-week low of Rs 628.1.

After losing the wealth-creation plot somewhat, the wheel of fortune is once again turning the GenNext Marwari way. Higher- quality education, exposure to global management techniques and better corporate governance have rekindled a new hunger for success among GNMs - GenNext Marwaris. A fresh upsurgence is on the way.

A total of 8,793 shares changed hands on the counter till 01:34PM (IST)

While fans eagerly await news of Lupin Season 4, series creator George Kay provides a glimpse into the potential future of the show following the captivating conclusion of Season 3.

#LUPIN 💸💸💸💸 Time frame 1hr~Lower low formation✅~Closed at a support✅~ A good RRR trade✅~INTRADAY to SWING✅Stop loss - ab

Netflix's most watched movies and series in the English and non-English categories have been unveiled.

The approval granted by the US Food and Drug Administration (USFDA) for the abbreviated new drug application of Fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg, Lupin said in a regulatory filing.

The product will be manufactured at Lupin’s Pithampur facility in India. Fluconazole tablets USP had estimated annual sales of $43 million in the US according to IQVIA MAT data in July 2023

As of 30-Sep-2023, promoters held 46.77 per cent stake in the company, while FIIs held 14.99 per cent and domestic institutional investors had 16.71 per cent.

On the technical charts, the RSI of the stock stood at 57.79.

The stock quoted a 52-week high of Rs 1215.2 and a 52-week low of Rs 628.1.

A total of 11,469 shares changed hands on the counter till 12:38PM (IST)

The recent Supreme Court ruling against same-sex marriages in India will not hinder the progress of inclusion in Corporate India, according to HR and diversity heads at leading companies. They believe that companies will continue to strive for inclusivity, as they have recognized the benefits it brings in terms of innovation and profitability. While a clearer verdict on marriage equality would have been helpful, companies are already taking steps to support LGBTQIA+ rights through various initiatives such as insurance coverage for partners, gender-neutral facilities, and ally programs.

The stock quoted a 52-week high of Rs 1214.75 and a 52-week low of Rs 628.1.

The stock quoted a 52-week high price of Rs 1201.1 and a 52-week low of Rs 628.1.

"Lupin," which debuted on Netflix in 2021, has garnered a dedicated following, thanks to its gripping storyline and outstanding performances.

The product will be manufactured at Lupin’s Pithampur facility in India.

Indian drug maker Lupin has received tentative approval from the US Food and Drug Administration (FDA) to market a generic medication used to reduce excessive daytime sleepiness. Lupin plans to produce the medication at its facility in Somerset, US.

​On the other hand, if somebody wants to play on very ultra short-term, maybe one or two days perspective, then we are still holding above 19,500-19,550 quite strongly, even 19,600 for that matter.

Several midcap stocks achieved unprecedented milestones by reaching new 52-week highs on October 12.

​​In a statement, IT industry body Nasscom said: “We condemn the horrific act of terrorism on Israel that has led to loss of innocent lives and precipitated the conflict. The technology industry in India, we value our partnership with Israel as an innovation hub and will continue to strengthen our engagements.” As regards the current crisis, the industry has a limited presence in Israel largely focused on innovation partnerships and R&D.

The stock quoted a 52-week high price of Rs 1184.0 and a 52-week low of Rs 628.1.

This product will be manufactured at Lupin’s Nagpur facility in India.

A total of 9,066 shares changed hands on the counter till 01:39PM (IST)

#LUPIN Lupin In 15min Time FrameFor IntradayBuy Above____ 1115Target____ 1130___ 1150

Multinational pharmaceutical company Johnson & Johnson (J&J) has announced that it will not enforce secondary patents for its anti-TB drug Bedaquiline in low and middle income countries. This means that Indian pharmaceutical companies will be able to supply generic versions of the drug without the fear of litigation.

The US FDA classified Lupin's Nagpur unit as Voluntary Action Indicated.

On the technical charts, the 200-day moving average of the stock stood at Rs 828.42.

A total of 5,653 shares changed hands on the counter till 12:58PM (IST).

The stock quoted a 52-week high of Rs 1174.25 and a 52-week low of Rs 628.1.

ANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduction in approval timeline and clearance of the backlog.

Lupin said it has inked a pact to acquire five drug brands from Italian firm Menarini for Rs 101 crore. The company has signed an agreement to acquire five legacy brands catering to gastroenterology, urology and anti-infective segments, the Mumbai-based company said in a statement.

Lupin has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with A. Menarini India Private Limited.

​We have seen some players recall some products. We have seen some players file bankruptcies. So these will therefore create opportunities for players with a wide portfolio.

Consistent Compounders is the flagship portfolio that invests primarily in largecap stocks that have high cashflow. Little Champs portfolio invests primarily in smallcap stocks.

As of 30-Jun-2023, promoters held 46.79 per cent stake in the company, while FIIs held 13.94 per cent and domestic institutional investors had 17.0 per cent.

A total of 12,150 shares changed hands on the counter till time (IST).

Under the business transfer agreement, the pharma major will move the two active pharmaceutical ingredients (APIs) manufacturing sites at Dabhasa and Visakhapatnam to the subsidiary.

As of 30-Jun-2023, promoters held 46.79 per cent stake in the company, while FIIs held 13.94 per cent and domestic institutional investors had 17.0 per cent.

On September 8, Friday, StockEdge reported that 27 stocks were trading in the overbought zone but had bearish or declining Relative Strength Index (RSI) trends.